Close Menu

    Subscribe to Updates

    Get the latest creative news from FooBar about art, design and business.

    What's Hot

    Air Arabia Egypt launches Cairo to Al Ain flights now

    November 20, 2026

    TÜV SÜD opens its International Technology & Innovation Campus in the Guangdong-Hong Kong-Macao Greater Bay Area

    November 20, 2026

    Huawei Unveils Financial AI Scaling Capabilities at Singapore FinTech Festival 2026

    November 20, 2026
    Facebook X (Twitter) Instagram
    • Home
    • Contact Us
    Benghazi DailyBenghazi Daily
    • Automotive
    • Business
    • Entertainment
    • Health
    • Lifestyle
    • Luxury
    • News
    • Sports
    • Technology
    • Travel
    Benghazi DailyBenghazi Daily
    Home » First Participants Vaccinated with IAVI’s Ebola Sudan Vaccine Candidate in Uganda Amid Ebola Outbreak
    ACCESS Newswire

    First Participants Vaccinated with IAVI’s Ebola Sudan Vaccine Candidate in Uganda Amid Ebola Outbreak

    February 3, 2025

    The vaccine candidate is being evaluated in a ring vaccination trial as part of a comprehensive public health response

    NEW YORK CITY, NY / ACCESS Newswire / February 3, 2025 / The first participants have been vaccinated with an investigational Ebola Sudan vaccine candidate provided by IAVI, a nonprofit scientific research organization, as part of a World Health Organization (WHO)-led ring vaccination trial taking place at Makerere University Lung Institute in Kampala. WHO prioritized evaluation of IAVI’s candidate vaccine, which was already prepositioned in Uganda, as part of a global collaborative effort supporting the country’s Ebola outbreak response.

    This is Uganda’s sixth outbreak of Ebola Sudan, which causes severe hemorrhagic fever disease with a case fatality rate of up to 50%. No licensed vaccines or therapeutics are available for Ebola Sudan, a Category A priority pathogen. Existing Ebola Zaire vaccines are not cross-protective for Ebola Sudan.

    Mark Feinberg, M.D., Ph.D., IAVI president and CEO, said: “IAVI is grateful for the efforts that the WHO, the Ugandan government, and our public health partners in Uganda have made in enabling the rapid deployment of our investigational Ebola Sudan vaccine candidate to address the ongoing outbreak of Ebola Sudan in Uganda. We believe this clinical trial represents an important step toward evaluating the potential of IAVI’s vaccine to protect exposed individuals from Ebola Sudan infection as well as demonstrating its value as a safe, effective, and accessible new tool to include in comprehensive outbreak responses in the future. Critically, having vaccine doses readily available in country made it possible for us all to mobilize in just days and to be able to incorporate evaluation of a promising Ebola Sudan vaccine clinical trial into the public health response very soon after the first reports of the current outbreak.”

    Uganda’s current Ebola outbreak began on Jan. 30 with a confirmed infection in a health worker who died in Kampala, and since then 45 contacts have been identified. Close contacts are at elevated risk of infection and are prioritized for inclusion in a ring vaccination trial.

    A study published recently in the New England Journal of Medicine confirms the high-level effectiveness of ring vaccination in containing Ebola outbreaks in the Democratic Republic of the Congo. The vaccine assessed in that study – ERVEBO®, Merck’s single-dose Zaire ebolavirus vaccine – uses the same recombinant vesicular stomatitis virus (rVSV) viral vector platform as IAVI’s Ebola Sudan vaccine candidate. ERVEBO® is licensed in more than a dozen countries.

    More about IAVI’s investigational Ebola Sudan vaccine candidate

    In 2023, IAVI initiated a Phase 1 clinical trial of its rVSV-based Ebola Sudan vaccine candidate. The study was designed to evaluate the Ebola Sudan vaccine candidate in healthy U.S. adult volunteers at three dose levels. Initial results from that study indicate that the candidate vaccine was well tolerated across all three groups; immune responses were also detected in all three groups. These data were shared in November 2024 during the annual meeting American Society of Tropical Medicine and Hygiene. As a follow-up to this study, IAVI and our partners are currently planning a Phase 1 study in Africa.

    In addition to being the backbone of the Ebola Sudan vaccine candidate, rVSV is the platform technology utilized in IAVI’s portfolio of emerging infectious disease (EID) candidates, including a Lassa virus vaccine candidate currently in Phase 2 clinical trials in West Africa, supported by the Coalition for Epidemic Preparedness Innovations (CEPI) and the European and Developing Countries Clinical Trials Partnership (EDCTP).

    Rose Catlos
    rcatlos@iavi.org
    +12128471049

    SOURCE: IAVI

    View the original press release on ACCESS Newswire

    Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

    Related Posts

    ACCESS Newswire

    Chevron Signs 3-Year Agreement with UptimeAI, Scaling Expertise to Enhance Asset Reliability and Operational Efficiency

    November 17, 2026
    ACCESS Newswire

    Pitches and Keynote Speakers Are Confirmed for Blue Magic Netherlands on November 17

    November 4, 2026
    ACCESS Newswire

    Chervon Names Jody Grimsley Senior National Account Manager

    November 2, 2026
    Latest News

    Air Arabia Egypt launches Cairo to Al Ain flights now

    November 20, 2026

    Botswana opens consultations on proposed 33 percent hike now

    November 19, 2026

    PM Modi meets Prince and Princess of Wales in New Delhi

    November 19, 2026

    DXB handles 50.4 million passengers in first nine months

    November 18, 2026

    Congo Ebola death toll reaches 5,568 as cases pass 11,000

    November 18, 2026

    Rand slips toward R17 as inflation and weak growth cloud outlook

    November 18, 2026

    Tunisia tourism revenues top $2.38 billion by end-October

    November 17, 2026

    UAE President and Venezuela’s acting leader discuss closer ties

    November 17, 2026

    Africa CDC says Congo Ebola outbreak still not under control

    November 16, 2026
    © 2026 Benghazi Daily | All Rights Reserved
    • Home
    • Contact Us

    Type above and press Enter to search. Press Esc to cancel.